REPLIMUNE GROUP, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.43 USD | -4.32% |
|
+0.31% | -23.72% |
| May. 16 | Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
| Apr. 08 | Replimune Group Provides Interim Results for Skin Cancer Therapy | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2025 * | - | Sales 2026 * | 22.76M | Capitalization | 396M |
|---|---|---|---|---|---|
| Net income 2025 * | -229M | Net income 2026 * | -228M | EV / Sales 2025 * | - |
| Net cash position 2025 * | 144M | Net cash position 2026 * | 167M | EV / Sales 2026 * | 10 x |
| P/E ratio 2025 * |
-1.85
x | P/E ratio 2026 * |
-2.42
x | Employees | 331 |
| Yield 2025 * |
-
| Yield 2026 * |
-
| Free-Float | 94.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on Replimune Group, Inc.
More recommendations
More press releases
More news
| 1 day | -4.32% | ||
| 1 week | +0.31% | ||
| Current month | +1.26% | ||
| 1 month | -0.31% | ||
| 3 months | -16.82% | ||
| 6 months | -38.17% | ||
| Current year | -23.72% |
1 week
6.27
7.01
1 month
5.867.27
Current year
5.869.50
1 year
5.8624.81
3 years
5.8640.22
5 years
5.8654.85
10 years
5.8654.85
| Managers | Title | Age | Since |
|---|---|---|---|
Sushil Patel
CEO | Chief Executive Officer | 52 | 21-05-02 |
Colin Love
FOU | Founder | 65 | 15-02-28 |
| Founder | 51 | 15-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paolo Pucci
BRD | Director/Board Member | 63 | 20-03-31 |
Joseph Slattery
BRD | Director/Board Member | 59 | 17-09-30 |
Robert Coffin
FOU | Founder | 58 | 15-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.09% | 0 M€ | 0.00% | - | |
| 0.05% | 0 M€ | 0.00% | - | |
| 0.03% | 746 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 6.44 | -4.17% | 964,908 |
| 24-05-16 | 6.72 | -1.32% | 931,429 |
| 24-05-15 | 6.81 | +1.49% | 553,697 |
| 24-05-14 | 6.71 | +1.82% | 528,023 |
| 24-05-13 | 6.59 | +2.81% | 408,108 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The Company's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The Company's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathways activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.44
USD
Average target price
13.56
USD
Spread / Average Target
+110.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.72% | 396M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
- Stock Market
- Equities
- REPL Stock
